Biliary cancer: utility of next-generation sequencing for clinical management
A large commercial sequencing series of 554 biliary cancers, including 85 gallbladder tumours, showed that gallbladder cancer has HER2 changes in about one in six and almost no IDH or FGFR changes, the mirror image of intrahepatic bile duct cancer.
Overview
Hybrid capture-based comprehensive genomic profiling was performed for 412 intrahepatic cholangiocarcinomas, 57 extrahepatic cholangiocarcinomas and 85 gallbladder carcinomas, and the mutational profile was correlated with outcomes of standard and experimental therapies for 321 patients. In gallbladder carcinoma the most frequent alterations were TP53 (59%), CDKN2A/B (19%), ARID1A (13%) and ERBB2 (16%); in intrahepatic tumours TP53 (27%), CDKN2A/B (27%), KRAS (22%), ARID1A (18%) and IDH1 (16%); in extrahepatic tumours KRAS (42%), TP53 (40%), CDKN2A/B (17%) and SMAD4 (21%).
FGFR (11%) and IDH mutations (20%) were mostly limited to intrahepatic tumours and appeared mutually exclusive. TP53 and KRAS mutations predicted poor survival in intrahepatic disease, FGFR2 alterations better survival, and patients with FGFR alterations had superior survival on FGFR-targeted therapy than on standard regimens (P = 0.006).
- Gallbladder carcinoma (n = 85): TP53 59%, CDKN2A/B 19%, ARID1A 13%, ERBB2 16%.
- FGFR alterations (11%) and IDH mutations (20%) were largely confined to intrahepatic cholangiocarcinoma and were mutually exclusive.
- FGFR-altered patients lived longer on FGFR-targeted therapy than on standard regimens (P = 0.006).
The clearest early head-to-head of the three biliary sites on one platform: for gallbladder cancer it made HER2 the target to test for and showed that IDH and FGFR inhibitors would rarely apply.
- Commercial referral cohort (FoundationOne), not population based.
- Outcome correlations were retrospective across mixed therapies.
Similar pages
not linked directly; found by shared links- Key paperPopulation-Specific Immunogenomic Alterations in Gallbladder Cancer and Prognostic Significance
Shares ARID1A, SMAD4, MD Anderson Cancer Center, TP53.
- Key paperGenomic profiling of Indian gallbladder carcinoma: mutational insights in a high-incidence population
- TermIntrahepatic, perihilar, distal and gallbladder cancer
Shares IDH1 / IDH2, FGFR2, HER2, Biliary tract cancer (cholangiocarcinoma).
- Key paperMolecular and clinical determinants of targeted therapy treatment in biliary tract cancer
- Key paperComprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention
- Key paperRegional differences in gallbladder cancer pathogenesis: insights from a multi-institutional comparison of tumor mutations
Shares ARID1A, SMAD4, Cancer, Gallbladder cancer.
- TrialKN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
- TrialThe Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.